Australia grants first approval worldwide to Pharmaxis' cystic fibrosis therapy
This article was originally published in Scrip
Pharmaxis has received the first regulatory clearance worldwide for its cystic fibrosis (CF) therapy Bronchitol, in its home market of Australia.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.